What's New in Obesity Treatment?
Presented Live at Pri-Med West 2017
Obesity is now recognized as a chronic illness that requires ongoing treatment, much like diabetes, hypertension, and hyperlipidemia. This is now encompassed by Obesity Medicine, the fastest-growing new specialty. In this keynote talk, Dr. Louis Aronne discusses multidisciplinary approaches to combating obesity, including prescription of diet, exercise, and behavioral modification. He will further review pharmacologic therapies, devices, and surgeries that can be considered as adjuncts to lifestyle interventions in appropriate patients.
• Discuss the impact of obesity on health
• Implement the components of a comprehensive treatment plan for obesity management, based on new guidelines
• Describe patient selection and safety criteria for anti-obesity medications and devices
Advisory board for Eisai Inc., GI Dynamics Inc., Jamieson Labs, Jovia, Novo Nordisk Inc., Pfizer Inc., and Vivus. Contracted research for Aspire Bariatrics and Eisai Inc. Ownership interest in Gelesis, Jamieson Labs, Myos Corporation, and Zafgen Inc.
Pamela Kushner, MD, FAAFP
Speaker’s Bureau for AstraZeneca; Janssen Pharmaceuticals, Inc.; and Lilly. Advisory Board for AstraZeneca; Janssen Pharmaceuticals, Inc.; and Pfizer, Inc. Services Provided for Promotional Purposes (not for CME/CE Services) for AstraZeneca and Janssen Pharmaceuticals, Inc.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.
Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email firstname.lastname@example.org or call (877) 477-4633.